<DOC>
	<DOCNO>NCT00083460</DOCNO>
	<brief_summary>The purpose study assess toxicity PS-341 combine one four dos thalidomide patient refractory multiple myeloma , find appropriate dos PS-341 thalidomide combination .</brief_summary>
	<brief_title>Study Combination PS-341 Thalidomide Multiple Myeloma</brief_title>
	<detailed_description>Patients enrol group 6-10 patient , receive low dose PS-341 ( 1.0 mg/m2 ) different dose level thalidomide ( 50 , 100 , 150 , 200 mg ) . The first six patient group receive PS-341 alone first cycle , thalidomide add day 22 . If combination find safe first 6 patient , remain patient group enrol . Initially , patient receive PS-341 alone thalidomide add subsequently , deem safe base first 6 patient thalidomide dose cohort .</detailed_description>
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Bortezomib</mesh_term>
	<mesh_term>Thalidomide</mesh_term>
	<criteria>History histologically document multiple myeloma relapse resistant disease , define previously treat with/without autologous stem cell transplantation either relapse resistant &gt; 1 line prior therapy myeloma Patients eligible MTRC phase III protocols high priority Performance status great equal 2 per SWOG scale Patients must absolute neutrophil count &gt; 750/mm3 , platelet count great equal 25,000/mm3 No prior malignancy allow except adequately treat basal cell squamous cell skin cancer , situ cervical cancer , cancer patient disease free least three year . Prior malignancy acceptable provide evidence disease within threeyear interval Pregnant nursing woman may participate . Women childbearing potential must negative pregnancy document within one week registration . Women/men reproductive potential may participate unless agree use effective contraceptive method . Male female adult least 18 year age . Signed write informed consent willingness meet followup schedule study procedure obligation Chemotherapy radiotherapy receive within previous 2 week Prior Treatment PS341 Significant neurotoxicity , define grade great equal 2 neurotoxicity per NCI Common Toxicity Criteria POEMS Syndrome Nonsecretory multiple myeloma Active infection require antibiotic Clinically significant hepatic dysfunction absence liver metastasis note bilirubin AST &gt; 3 time upper normal limit clinically significant concurrent hepatitis New York Hospital Association ( NYHA ) Class III Class IV heart failure Myocardial infarction within last 6 month Poorly control hypertension , diabetes mellitus , serious psychiatric illness could potentially interfere completion treatment accord protocol Severe renal dysfunction define creatinine clearance &lt; 20 cc/min . Absolute neutrophil count &lt; 750/mm3 , platelet count &lt; 25,000/mm3 Pregnant potential pregnancy Breastfeeding</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2010</verification_date>
	<keyword>Multiple Myeloma</keyword>
	<keyword>Thalidomide</keyword>
	<keyword>Velcade</keyword>
	<keyword>PS-341</keyword>
	<keyword>Refractory</keyword>
	<keyword>Bortezomid</keyword>
</DOC>